Breast Cancer Update: A CME Audio Series and Activity

STATEMENT OF NEED / TARGET AUDIENCE

Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from a plethora of ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well-informed of these advances. To bridge the gap between research and patient care, Breast Cancer Update uses one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists in the formulation of up-to-date clinical management strategies.

GLOBAL LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Critically evaluate the clinical implications of emerging clinical trial data in breast cancer treatment.
• Describe and implement an algorithm for HER2 testing and treatment of patients with HER2-positive breast cancer.
• Develop and explain a management strategy for treatment of ER-positive breast cancer in the adjuvant, neoadjuvant and metastatic settings.
• Develop and explain a management strategy for treatment of ER-negative breast cancer in the adjuvant, neoadjuvant and metastatic settings.
• Counsel postmenopausal patients with ER-positive breast cancer about the risks and benefits of aromatase inhibitors in the adjuvant setting.
• Evaluate the emerging data on dose-dense chemotherapy and explain its relevance to patients.
  

SPECIFIC LEARNING OBJECTIVES FOR ISSUE 8

Upon completion of this activity, participants should be able to:

• Evaluate clinical research data regarding the sequencing of fulvestrant in postmenopausal women with hormone receptor-positive, metastatic breast cancer and consider the clinical implications for the management of these patients.
• Provide a rationale for the selection of single chemotherapy agents and combination regimens in the metastatic setting.
• Describe the clinical trials of first-line trastuzumab in the metastatic setting and ongoing adjuvant clinical trials with trastuzumab in order to counsel appropriately selected patients about nonprotocol and clinical trial options.
• Discuss the postulated phases and mechanisms of resistance to hormonal therapies and potential strategies to overcome resistance.
  

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3.25 category 1 credits towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent on the activity.

Home · Search